Table 4.
Persistent/recurrent disease at the end of follow-up in vaccinated and non-vaccinated women related to the first post-conization control status. Values are absolute numbers and percentages.
| Clinical Outcome at the End of Follow-Up | ||||
|---|---|---|---|---|
| Status at the First Post-Conization Control (6 Months) | No Disease | Persistent/Recurrent LSIL/HPV | Persistent/Recurrent HSIL | p * |
| No disease (n = 153) | 0.032 | |||
| Non-vaccinated | 55 (83.3) | 7 (10.7) | 4 (6.1) | |
| Vaccinated | 78 (89.7) | 9 (10.3) | 0 (0.0) | |
| Persistent LSIL/HPV (n = 101) | 0.173 | |||
| Non-vaccinated | 28 (65.1) | 9 (20.9) | 6 (14.0) | |
| Vaccinated | 33 (56.9) | 21 (36.2) | 4 (6.9) | |
| Persistent HSIL/CIN2-3 (n = 11) | 0.131 | |||
| Non-vaccinated | 0 (0.0) | 1 (33.3) | 2 (66.7) | |
| Vaccinated | 3 (37.5) | 4 (50.0) | 1 (12.5) | |
LSIL: low-grade squamous intraepithelial lesion; HPV: human papillomavirus; HSIL/CIN2-3: high-grade squamous intraepithelial lesion/cervical intraepithelial neoplasia grade 2–3. Status at first control post-conization are defined as follows: (1) persistent HSIL (histologically confirmed HSIL/CIN2-3); (2) persistent LSIL/HPV (abnormal cytology of any grade, and/or positive HPV test result, with biopsy diagnosis of LSIL/CIN1 or negative or no biopsy performed), and (3) no disease (negative HPV test, negative Pap test, and if available, negative biopsy). (1) persistent/recurrent HSIL (presence of histologically confirmed HSIL/CIN2-3, or a repeated HSIL result in at least two Pap smears separated by six months and positive HPV testing result, independently of the histological diagnosis); (2) persistent/recurrent LSIL/HPV (persistent abnormal cytological result of LSIL, ASC-US or AGUS, a single cytology result of HSIL and/or a positive HPV test result without histological diagnosis of HSIL/CIN2-3); and (3) no disease (negative HPV test, negative Pap test, and, if available, a negative biopsy). * Fisher exact test.